Tao Qiu

Q: What is Tao Qiu's success rate?

Tao Qiu currently has a success rate of 100.

Q: What is the average return of Tao Qiu's calls?

Their stock ratings have generated an average return of 90.7309721175584.

Macquarie | Healthcare

Tao Qiu is an analyst from Macquarie specializing in the Healthcare sector. They are beginning to establish their track record, with 1 stock rating so far. Their current stats show a success rate of 100.00% and an average return of 90.73%.

Tao Qiu has only issued 1 rating so far. While the sample size is small, their early calls show a success rate of 100.00% and an average return of 90.73%. Investors may find their initial activity in the Healthcare sector worth watching as they build a track record.

#115

Out of 4771

Total Ratings

+100.00%

Success Rate

+90.73%

Average Return

Recent Ratings Analysis

HCSG

Buy

Jul 29, 2025

Target

$16.00

Current

$21.84

Performance

64.58%

Tao Qiu rated HCSG as Outperform on Jul 29, 2025, setting a price target of 16. The call has proven timely, with shares rising 64.58% toward the price target of 16.

BKD

Buy

Mar 12, 2025

Target

$8.00

Current

$12.20

Performance

114.41%

On Mar 12, 2025, BKD was given a Outperform rating by Tao Qiu, with a target price of 8. The stock rallied 114.41% after the rating, narrowing the gap to the target of 8 and validating the bullish stance.

SGRY

Buy

Mar 11, 2025

Target

$33.00

Current

$14.12

Performance

-40.25%

SGRY received a Outperform rating from Tao Qiu on Mar 11, 2025, aiming for 33. The rating hasn’t played out as hoped, with the stock trading 40.25% below expectations.

ADUS

Buy

Feb 27, 2025

Target

$129.00

Current

$118.52

Performance

22.50%

On Feb 27, 2025, Tao Qiu published a Outperform outlook on ADUS, with a target of 129. Shares gained 22.50%, underscoring the accuracy of the bullish outlook toward 129.

ENSG

Buy

Feb 04, 2025

Target

$166.00

Current

$172.79

Performance

18.86%

Tao Qiu on Feb 04, 2025 assigned ENSG a Outperform rating, with a price target of 166. The Buy call aligned well with market performance, producing a gain of 18.86%.

PACS

Buy

Jan 06, 2025

Target

$24.00

Current

$44.85

Performance

235.70%

On Jan 06, 2025, Tao Qiu reaffirmed PACS with a Outperform rating, targeting 24. The recommendation was supported by strong follow-through as the stock rose from 44.85 to 44.85.

PRVA

Buy

Dec 16, 2024

Target

$25.00

Current

$20.37

Performance

-6.86%

PRVA was rated Outperform by Tao Qiu on Dec 16, 2024, with a price objective of 25. This case shows how bullish projections can fail, with the stock now below 20.37.

AGL

Hold

Dec 16, 2024

Target

$3.00

Current

$92.60

Performance

69.13%

On Dec 16, 2024, Tao Qiu initiated coverage on AGL with a Neutral rating and target of 3. The Hold stance underestimated the stock’s strength as it gained 69.13%.

MD

Buy

Dec 16, 2024

Target

$18.00

Current

$26.73

Performance

84.98%

Tao Qiu issued a Outperform recommendation for MD on Dec 16, 2024, price target set at 18. Investors following the Buy call captured upside momentum, with shares now at 26.73.

Frequency Asked Questions

Who is Tao Qiu?

Tao Qiu is an analyst from Macquarie specializing in the Healthcare sector.

What is Tao Qiu's success rate?

Tao Qiu currently has a success rate of +100.00%.

How many ratings has Tao Qiu issued?

Tao Qiu has issued 1 stock ratings so far.

What is the average return of Tao Qiu's calls?

Their stock ratings have generated an average return of +90.73%.

What is Tao Qiu's ranking?

Tao Qiu is ranked #115 out of 4771 analysts.

What types of ratings does Tao Qiu give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Tao Qiu?

You can follow Tao Qiu by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Tao Qiu?

Their latest rating was a Buy on HCSG issued on 2025-07-29.